Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Accenture
Farmers Insurance
Johnson and Johnson
Fish and Richardson
Deloitte
Queensland Health
Covington
McKesson

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,048,917

« Back to Dashboard

Which drugs does patent 8,048,917 protect, and when does it expire?

Patent 8,048,917 protects HORIZANT and is included in one NDA.

This patent has seventy patent family members in twenty countries.
Summary for Patent: 8,048,917
Title:Prodrugs of GABA analogs, compositions and uses thereof
Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Inventor(s): Gallop; Mark A. (Los Altos, CA), Cundy; Kenneth C. (Redwood City, CA), Zhou; Cindy X. (Palo Alto, CA), Yao; Fenmei (Mountain View, CA), Xiang; Jia-Ning (Palo Alto, CA)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Application Number:11/110,909
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,048,917

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ➤ Sign Up
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,048,917

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,708 Prodrugs of GABA analogs, compositions and uses thereof ➤ Sign Up
6,972,341 Prodrugs of GABA analogs, compositions and uses thereof ➤ Sign Up
6,818,787 Prodrugs of GABA analogs, compositions and uses thereof ➤ Sign Up
7,423,169 Methods for synthesis of acyloxyalkyl derivatives of GABA analogs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Argus Health
Merck
Chubb
McKesson
Federal Trade Commission
Colorcon
Medtronic
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.